Back to News Items

August 2012 : New Article: Crizotinib is a unique treatment for non-small cell lung cancer

        Main Bullet points:

  • The American Cancer Society indicates that the rate for men in the U.S. to develop Non- Small Cell Lung Cancer is one in thirteen, and for women the risk is one in sixteen.
  • Crizotinib is a unique treatment for non-small cell lung cancer, as it specifically targets the Anaplastic Lymphoma Kinase, or ALK gene in patients.
  • Bloomberg has reported a sales projection indicating that the sale of Crizotinib will produce upwards of 540 million dollars by 2015.
  • Crizotinib is essential for treating NSCLC (Non-small cell lung cancer), which represents 85 percent of the lung cancer patient population, according to formulary online.
  • Recent news has researchers looking at another exciting potential use for Crizotinib, specifically in the treatment of anaplastic large cell lymphoma and neuroblastoma in children.
  • Crizotinib is poised to become a widely used therapy to target a variety of cancer types in patients with ALK mutations.




Dun and Bradstreet